ISSN (print) - 0131-7652

ISSN (online) - 2686-7605

Vol. 51 No. 8 (2021)
Тема номера: Пространство локализации

Pharmaceutical Production in Russia during the Pandemic: Chronic Problems, New Challenges

PDF (Русский)
  • T. Dolgopyatova,
  • A. Fedyunina,
  • A. Nazarova
T. Dolgopyatova
Institute for Industrial and Market Studies, National Research University Higher School of Economics, Moscow
A. Fedyunina
Center for Structural Policy Research, National Research University Higher School of Economics, Moscow
A. Nazarova
Centre of Development Institute, National Research University Higher School of Economics, Moscow
DOI: https://doi.org/10.30680/ECO0131-7652-2021-8-38-63

Published 2021-08-02

Keywords

  • pharmaceutical production,
  • pharmaceutical market,
  • COVID-19 pandemic,
  • crisis,
  • anticrisis support,
  • public regulation
    • ...More
    Less

How to Cite

1.
Dolgopyatova Т, Fedyunina А, Nazarova А. Pharmaceutical Production in Russia during the Pandemic: Chronic Problems, New Challenges. ECO [Internet]. 2021 Aug. 2 [cited 2024 Jul. 31];51(8):38-63. Available from: https://ecotrends.ru/index.php/eco/article/view/4294

Abstract

Using a series of in-depth interviews with representatives of the industry and national and international statistical data, the authors examine the role of pharmaceutical production in the Russian economy before and during the crisis, the impact of the COVID-19 pandemic on companies and markets, the specifics of regulation, and business development prospects.The main conclusion is that the crisis has not brought significant changes in the state of the industry, it continues to be under pressure from the state, the policy of import substitution, preferential regulation of state procurement of drugs, restrictions on the price level for drugs. Competition between Russian companies and foreign firms that have localized production in our country is getting tougher.
PDF (Русский)

References

  1. Андреева Е. Л., Сапир Е. В., Карх Д. А., Карачев И. А. Компаративный анализ внешнеэкономического развития фармацевтического сектора в РФ и США // Экономика региона. 2019. Т. 15. № 2. С. 576–589.
  2. Борзова М., Чередова А. Локализация фармацевтических производств // Ремедиум Приволжье. 2017. Т. 1. № 151. С. 6–9.
  3. Лин А. А., Соколов Б. И., Слепнев Д. М. Фармацевтический рынок: производство лекарственных средств в России // Проблемы современной экономики. 2013. Т. 1. № 45. С. 191–195.
  4. Мамедьяров З. А. Тенденции и перспективы российской фармацевтической отрасли и применимость мирового опыта // МИР (Модернизация. Инновации. Развитие). 2017. Т. 8. № 4. С. 772–780.
  5. Мантуров Д. В. Промышленная политика в российской фармацевтической отрасли // Экономическая политика. 2018. Т. 13. № 2. C. 64–77.
  6. Сапир Е. В., Карачев И. А. Общий фармацевтический рынок ЕАЭС и евразийская интеграция // Современная Европа. 2017. Т. 2. № 74. С. 121–134.
  7. Трофимова Е. О. Российский фармацевтический рынок: в русле общемировых трендов // Ремедиум. Журнал о российском рынке лекарств и медицинской технике. 2013. № 7–8. С. 71–75.
  8. Blankenship K. Pfizer plans to farm out manufacturing for some of its drugs to make way for COVID-19 vaccine // Fierce Pharma. 11 May 2020. URL: https://www.fiercepharma.com/manufacturing/pharma-pushes-back-u-s-legislation-to-bring-drug-manufacturing-stateside (дата обращения: 21.03.2021).
  9. Crotti N. DOD launches $100m initiative to return COVID-19-related medtech pharma manufacturing to the U. S. MassDevice Medical Network. 22 Jun. 2020. URL: https://www.massdevice.com/dod-launches-100m-initiative-to-return-covid-19-related-medtech-pharma-manufacturing-to-the-u-s/ (дата обращения: 18.03.2021).
  10. Evans J., Meisenheimer J. COVID-19 - Suffocating the global medical supply chain… while breathing life into its future // Site Selection. Apr. 2020. URL: https://siteselection.com/investor-watch/covid-19-suffocating-the-global-medical-supply-chain-while-breathing-life-into-its-future.cfm (дата обращения: 21.03.2021).
  11. Leo L. 30% import limit for bulk drug makers getting sops. E-paper «MINT». 27 July 2020а. https://www.livemint.com/politics/policy/30-import-limit-for-bulk-drug-makers-getting-sops-11595812233082.html (дата обращения: 02.04.2021).
  12. Leo L. Govt finalizing guidelines for scheme to boost API manufacturing. E-paper «MINT». 13 July 2020b. URL: https://www.livemint.com/news/india/govt-finalising-guidelines-for-scheme-to-boost-api-manufacturing-11594651505910.html (дата обращения: 02.04.2021).
  13. Levy S. Pharmaceutical shipping costs spike in response to global COVID-19 pandemic. 30 Apr. 2020. URL: https://drugstorenews.com/aam-survey-pharmaceutical-shipping-costs-spiked-due-pandemic (дата обращения: 20.03.2021).
  14. Mullin R. COVID-19 is reshaping the pharmaceutical supply chain. Chemical & Engineering News. 27 Apr. 2020. Vol. 98, Iss. 16. URL: https://cen.acs.org/business/outsourcing/COVID-19-reshaping-pharmaceutical-supply/98/i16?fbclid=IwAR2VZ4v14–1I5g8Pw4fH_hvj04kTCW5YK8OjpOmOXrxu-tY9BkCU_cE8qAk&referral=939AF62E-38A9–49C0-A8F5-C7B3AF933437 (дата обращения: 10.03.2021).
  15. Riley D. L., Strydom, I., Chikwamba R., Panayides J.-L. Landscape and opportunities for active pharmaceutical ingredient manufacturing in developing African economies. Reaction Chemistry & Engineering. 2019. Vol. 4. No.3. Pp. 457–489. DOI: 10.1039/C8RE00236C
  16. Van Arnum P. Re-configuring global pharma supply chains. DCAT Value Chain Insights. 8 Jul. 2020. URL: https://www.dcatvci.org/6622-re-configuring-global-pharma-supply-chains (дата обращения: 25.03.2021).